日前，赛升药业（300485）发布公告称，近日，公司收到马丽、刘淑芹出具的《股份减持计划告知函》。 按照赛升药业最新收盘价12.08元/股粗略计算，马丽、刘淑芹此次合计减持或将套现约1.2亿元。 截至本公告披露日，马丽持有公司股份29,846,791股(占公司当前总股本481,666,400股的6.2%)，刘淑芹持有公司股份8,748,000股(占公司当前总股本 481,666,400股的1.82%)，马丽和刘淑芹均为公司控股股东、实际控制人马骉的一致行动人。 据赛升药业2025年半年报，马骉和马丽为兄妹关系，刘淑芹为马骉和马丽的母亲。 资料显示，北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。 业绩方面，赛升药业净利润已连续三年下降，2022年、2023年、2024年公司净利润分别为2.05亿元、1.03亿元、-6885.31万元，分别同比下降49.11%、 49.73%、166.90%。 马丽和刘淑芹计划在自本公告披露之日起15个交易日后的3个月内(即:2025年10月21日至2026年1月20日)，通过集中竞价和大宗交易方式减持公 ...

Core Viewpoint - The recent legal issues surrounding Zhang Qinghua, the controlling shareholder of Fangsheng Pharmaceutical, are linked to insider trading activities that occurred between 2017 and 2018, resulting in significant financial losses for him and others involved [1][2][3]. Company Overview - Fangsheng Pharmaceutical focuses on innovative traditional Chinese medicine and was listed in 2014. Its core products address various medical fields, including cardiovascular, pediatric, musculoskeletal, gynecological, respiratory, and anti-infection treatments [1]. - As of the end of 2024, Zhang Qinghua directly holds 35.53% of Fangsheng Pharmaceutical's shares, and his investment management company holds an additional 2.08% [3]. Financial Performance - In 2024, Fangsheng Pharmaceutical reported a revenue of 1.777 billion yuan, representing a year-on-year increase of 9.15%, and a net profit attributable to shareholders of 255 million yuan, up 36.61% [4]. - For the first quarter of 2025, the company recorded a revenue of 418 million yuan, a decrease of 4.6% year-on-year, while the net profit reached 88 million yuan, an increase of 25.74% [4]. Legal Context - Zhang Qinghua's insider trading activities are associated with a major asset restructuring involving the acquisition of Haikou Qili Pharmaceutical Co., which was publicly announced in early 2018. The insider information sensitive period was from December 13, 2017, to February 4, 2018 [2]. - The China Securities Regulatory Commission (CSRC) has previously issued an administrative penalty against Zhang Qinghua for these actions, and he is now facing potential criminal charges [5]. Implications of Legal Proceedings - The legal proceedings highlight the complexities of securities law enforcement in China, where administrative penalties can precede criminal charges. The distinction between administrative violations and criminal offenses is significant, with different standards of proof required [5]. - The recent decision to grant Zhang Qinghua bail does not imply guilt but indicates ongoing legal scrutiny regarding the insider trading allegations [5].

Group 1 - The stock price of Tailong Pharmaceutical closed at 6.66 yuan on August 4, 2025, down 0.16 yuan or 2.35% from the previous trading day [1] - The opening price was 7.15 yuan, with a highest price of 7.15 yuan and a lowest price of 6.59 yuan, indicating significant intraday volatility [1] - The trading volume was 1,148,600 hands, with a transaction amount of 777 million yuan and a turnover rate of 20.01% [1] Group 2 - Tailong Pharmaceutical operates in the traditional Chinese medicine manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company's product range includes cold medicines, cardiovascular drugs, and digestive system medications, covering multiple therapeutic areas [1] Group 3 - On August 4, the company experienced rapid fluctuations in stock price, with a rebound of over 2% within 5 minutes around 9:40 AM, followed by a decline of over 2% within 5 minutes around 9:45 AM [1] - The net outflow of main funds on that day was 79.01 million yuan, accounting for 2.07% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 27.16 million yuan, representing 0.71% of the circulating market value [1]